Navigation Links
Sangamo BioSciences Reports Second Quarter 2009 Financial Results
Date:7/29/2009

ensation which totaled $0.8 million in the second quarter of 2009 compared to $0.6 million in the same period in 2008.

Total operating expenses for the second quarter of 2009 were $9.9 million, compared to $10.8 million for the same period in 2008.

Net interest and other income was $0.6 million for the second quarters of both 2009 and 2008.

Six Month Results

For the six months ended June 30, 2009, the consolidated net loss was $11.3 million, or $0.28 per share, compared to a consolidated net loss of $15.4 million, or $0.38 per share, for the six-month period ended June 30, 2008. Revenues were $7.9 million for the first half of 2009, compared to $5.6 million in the same period in 2008. Total operating expenses were $20.1 million for the first half of 2009 and $22.4 million in the first half of 2008. The decrease in operating expenses for 2009 was primarily associated with decreased manufacturing, preclinical and decreased lab supply expenses partially offset by increased clinical trial expenses.

Recent Highlights

  • Presentation of positive Phase 2 ZFP Therapeutic data at ADA 2009. Sangamo announced the presentation of previously unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA). Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. The data have enabled the definition of a responder population for SB-509 for future clinical trials.
  • Achievement of key milestone in cell engineering agreement with Genentech. A key research milestone was achieved in Sangamo's Research a
    '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
3. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
4. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
5. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
6. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
7. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
8. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
9. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
10. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/57b5qj/global_pdt ... "Global PDT Machine Industry Report 2014" report ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The Global PDT ... in-depth study on the current state of the ... overview of the industry including definitions, classifications, applications ...
(Date:6/1/2015)...  Boston-based Veritas Genetics is launching its mission ... personalized medicine and prevention to the forefront, allowing ... Beginning with its first product, a genetic screen ... Genetics is making its products affordable and accessible, ... genetic data which will be shared with the ...
(Date:6/1/2015)... ROUGE, La. , June 1, 2015 ... Phase II trial of lead candidate EP-100 in ovarian ... membrane-disrupting peptide designed to seek and destroy cancer cells ... surfaces. LHRH receptors are over-expressed in a wide range ... randomized, multi-center Phase II trial of EP-100 were ...
(Date:6/1/2015)... -- Shire plc (LSE: SHP, NASDAQ: ... the Jefferies 2015 Global Healthcare Conference in ... 2015. Jeff Poulton , Chief Financial Officer will ... a.m. ET (3:00 p.m. BST). A live ... Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/year-2015.aspx ...
Breaking Biology Technology:Global PDT Machine Industry Report 2014 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... ... camera during an operation he performed for his Discovery Channel television special: Silent Stalker: ... ... Show used VizVOCUS,s popular "plug and play" medical camera during an ...
... England , May 25, 2010 Executives from Heptares,Therapeutics (Welwyn ... of the agreement under which O2h provides multi-FTE -synthetic,chemistry services to support ... , ... said, "We are happy to have signed,this new contract with O2h; they ...
... China , May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... leading over-the-counter Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... it has,commenced assembly of its production line for its proprietary Zushima ... ...
Cached Biology Technology:VizVOCUS's Digital Camera Used by Dr. Mehmet Oz on Discovery Channel Special 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Mayo Clinic-led researchers is first to devise a system ... killer that hunts down and destroys cancer cells -- ... an advanced electronic article of Nature Biotechnology. , The ... cells, and then redirected the virus to attack diseased, ...
... prenatal care, new research suggests that early infection may ... on the immune system. Researchers at the University of ... a one-time infection as newborns didn't learn as well ... after their immunity was challenged. The research is in ...
... that the antibiotic minocycline might help alleviate HIV's negative ... that can develop even though antiretroviral therapy controls the ... with simian immunodeficiency virus (SIV), a very close relative ... to brain cells, less brain inflammation, and less virus ...
Cached Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Vybrant® Multidrug Resistance Assay Kit...
... Platypus Contact Printing Kit contains choice ... with series of 100 / 200 micron ... or 200 um x 10 mm lines, ... 20, 40 or 60 nm and pitch ...
Request Info...
Biology Products: